Pipeline Boasts First-in-Class Entries, Drugs in Crowded Areas
More and more of the pharma pipeline consists of specialty drugs. Going forward in 2020, areas that may see a lot of activity include biosimilars, orphan drugs and gene therapies, as well as potentially the first FDA-approved drug for Alzheimer’s and the first for nonalcoholic steatohepatitis (NASH).
More orphan drugs are expected to launch this year, continuing a trend examined in an issue brief by America’s Health Insurance Plans (AHIP) released in August 2019. Researchers found that 10% of all drug approvals in 1998 were orphan products, but by 2017, that percentage had risen to 44%.
Related Posts

May 11
Study Finds Fertility Program Prevents Medication Waste, Loss, Missed Doses
READ MORE
May 11
AbbVie Files Lawsuit Against Alternate Funding Company Payer Matrix Alleging ‘Fraudulent and Deceptive Scheme’
READ MORE
May 11